Amgen and Astellas Announce Japanese Link

US biotechnology giant Amgen has entered a partnership with Astellas Pharma of Japan in order to provide for the medical needs of Japanese patients, reports

A new business model, combining both companies’ capabilities has been agreed. Amgen’s pipeline candidate drugs are to be joined with Astellas’ knowledge and presence in the Japanese market. Five of Amgen’s pipeline developments, for the treatment of diseases of a cardiovascular nature as well as cancer, are set to be further commercialised and progressed.

A joint venture company will also be established, with the name Amgen Astellas BioPharma, with the intention of enabling Amgen to quickly establish a significant presence in Japan. This is expected to be set up and running by 1st October 2013.

Are you looking for a job in the science industry?

Click here to see our current science jobs

Pharmaceutical Jobs      

Posted in General, Industry News, Mobile News, NewsTagged in , , , , , , , , , , ,

Senior Clinical QA Auditor Job – London, UK

Working in support of a busy drug development team, as Senior Clinical QA Auditor you will plan, execute and report on Phase I and II clinical trials.

These audits will be both internal and external and include Investigator Sites, laboratories, documentation, TMFs and databases. Although the focus will be mainly GCP you will occasionally be involved with GCLP, GLP and GMP auditing. Other activities will include assisting in staff training, representing the organisation at conferences and the review and update of SOPS.


Qualifications and Requirements:

  • BSc or Nursing qualification
  • QA auditing experience gained within clinical trials
  • A good understanding of Good Clinical Practice
  • Knowledge of GLP and GMP requirements
  • Excellent communication skills


Apply Now

For more information, or to apply for this Senior Clinical QA Position, please contact Jim Gleeson at CK Clinical on 01438 870 027 or email

 Alternatively,  click here to apply for this Senior Clinical QA  Auditor job online now.

Posted in General, NewsTagged in , , ,

Synthetic Organic Chemist – UK

We are currently searching for Synthetic Organic Chemists to join a global pharma company based in Hertfordshire, UK.

As a Synthetic Organic Chemist, you will be experienced in Synthetic Organic Chemistry and will have an understanding of drug development. Any experience in Medicinal Chemistry, DMPK, SAR or CNS drug discovery would also be a distinct advantage for this Synthetic Organic Chemist job.

The ideal candidate for this Synthetic Organic Chemist job will also be experienced in the delivery of small molecules and will be able to undertake independent planning, troubleshooting and successful execution of efficient synthetic routes to novel compounds.

You will hold a minimum of a degree in Chemistry/Synthetic Organic Chemistry (or equivalent) and will have practical ability in Organic Chemistry and a contemporary knowledge of Synthetic Organic Chemistry. You will have the ability to solve complex synthetic problems and to conduct multistep synthesis. It is essential that you are highly motivated and have the ability to adapt to changing priorities. You will also have an understanding of the importance to deliver the end product/final compound.

Apply now

For more information, or to apply for this Synthetic Organic Chemist job, please contact Jason at CK Science on 01438 723 500 or email Please quote reference ST20084 in all correspondence.

Alternatively, click here to apply for this Synthetic Organic Chemist job online now.

Not quite what you’re looking for? Click here to register your CV with CK Science now.

Posted in General, NewsTagged in , , , , , , , , , , ,

GSK Team Up with the University of Manchester

Science JobsIn partnership with the NIHR Manchester Biomedical Research Centre, scientists at the University of Manchester and GlaxoSmithKline (GSK) will be working together to investigate how the biological clock controls inflammation in lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD).

It is hoped that the £500,000 study, which will be funded by GSK, will lead to the development of new drugs that will target how the internal body clock regulates the severity of inflammation. The team at the University of Manchester will be headed up by Professors Andrew Loudon, David Ray and Kath Else. This team will work closely with colleagues in the Discovery Biology group at GSK.

Speaking of the collaboration, Professor Loudon or the faculty of life sciences, stated:

“Many inflammatory diseases are highly rhythmic in presentation and often worse at night. We believe there is also a strong rhythmic control. It has long been speculated that asthma and other inflammatory conditions have an underlying clock mechanism controlling the severity of the disease. These clocks are all over the body, including in cells responsible for the immune response in the lung. In addition the way we metabolise drugs is highly rhythmic. Our aim is to gain a sufficient understanding of this process so we can target key parts with specific new drugs.

“We are working with GSK not only to develop new drugs to alleviate symptoms but also reveal optimal timing of therapy, known as chronotherapy. This is a new and exciting area of research. It is being taken very seriously in France, for example, where researchers have for some time been studying the importance of timing of chemotherapy in cancer. This study is just one at the beginning of an exciting new phase in circadian rhythm research.”

Inflammatory diseases of the lung are a major cause of mortality world-wide. In the case of COPD, the progression of this inflammatory disease is irreversible once commenced. In the UK 27,478 people died as a result of COPD in 2004. Other diseases with an inflammatory aspect include asthma, which is a predisposition to chronic inflammation of the lungs in which the airways are reversibly narrowed.

Search for the latest pharmaceutical and science jobs now.

CKS01twittercksciencelinkedinfacebookckclinical youtube

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , ,

GSK Offers to Share Scientific Data to Wipe Out Tropical Diseases


In recent years, pharmaceutical companies have come under increasing pressure to change their approach to providing cheap drugs to people in the developing world. Many have faced fierce criticism for their failure to drop prices for HIV drugs while millions died in Africa and Asia, for defending patents. However, it seems the Chief Executive of GSK, Andrew Witty has a plan to fix this problem.

As reported in the Daily Telegraph, GSK is planning to share scientific data and laboratories in a bid to wipe out tropical diseases, such as malaria.  Andrew Witty, the Chief Executive of GSK who recently spent time in some of the world’s poorest continents, including Africa, said the global pharmaceutical company has a “genuine appetite to change the landscape of healthcare for the world’s poorest people”. In fact, it is estimated that Africa carries 70% of the world’s healthcare burden, but only receives 3% of healthcare resources.

In 2009, GSK announced it would create a patent pool for some of its existing products and not-for-profit-pricing on a variety of drugs for the developing world. In addition, the pharmaceutical giant plans to release 13,500 of its compounds that are believed to have the potential to be developed into new malaria treatments.

GSK will also operate an ‘Open Lab’ scheme whereby the company will open one of its laboratories in Tres Santocs, Spain, for non-GSK scientists to use to investigate treatments for other tropical diseases. The lab will accommodate 60 scientists who will benefit from £4.9m of funding from GSK to help with their research.  Speaking of this innovative ‘Open Lab’ scheme, Witty stated, Speaking before leaving for New York, Mr. Witty said: “Malaria is a dreadful disease which stalks the fields and villages of many parts of the least developed world. It has been an intractable problem for decades. Enormous progress has been made through bed net programmes, for example, but a really effective treatment has been somewhat elusive. We need to enlist the help of scientists around the world and to make it as easy as possible for that brilliant scientist, wherever they are, to find that initial spark that could be the breakthrough.”

Posted in General, NewsTagged in , , , , , , , , , , , , , , , , ,

Senior Manufacturing Scientist based in the Central Belt of Scotland

Our client, a world-class biotechnology company based in the Central Belt of Scotland, are currently seeking a Senior Manufacturing Scientist to be responsible for ensuring the contract manufacture of IMP/APIs to GMP standard.As a Senior Manufacturing Scientist you will maintain GMP compliance and assist in the effective technical transfer of projects. Further responsibilities will include:

– Performing activities related to the contract manufacture of Investigational Medicinal Products

– Identifying and resolving procedural/equipment/manufacturing problems and deviations, while requiring minimal line management direction.

– Monitoring equipment to ensure continued calibration and maintenance, and that all equipment used in the manufacturing process and any new equipment is validated for its particular use.

– Liaising closely with the Director of Operations for the effective planning and technical transfer of projects from Development to GMP manufacturing according to project plans by providing specialist technical knowledge and practical expertise, ensuring all relevant documentation is in place.

The successful candidate will have a qualification in a Life Science or Biological Science discipline and/or 3-5 years relevant practical experience. It would be desirable if you have an understanding and experience of Stem Cells Culture, bacterial fermentation or mammalian bioreactor vessels. Knowledge of Mammalian Cell Culture is essential.

This role will be initially temporary for 6 months with a strong likelihood of going permanent thereafter.

If you believe you are the right person for this Senior Manufacturing Scientist job, please contact Heather Deagle on 0191 3848905 or email

CK Science is the leading independent scientific recruitment agency for science jobs. We provide an all round scientific recruitment service to the chemical, pharmaceutical, biotechnology, waste, food, environmental and other related industries right across the UK.

Our team of specialist scientific recruiters and career consultants are here to help you achieve your career ambitions within the scientific industry. We can actively offer you careers advice, help with writing your CV, assistance with your interview preparation and up to date information about the industry.

– Visit our website

– Follow CK Science on Twitter

– Join the CK Science LinkedIn Group

– Become a fan of CK Science on Facebook

– To meet our consultants and hear more about our current vacancies, please visit our YouTube Channel

Keywords: Mammalian cell culture, science jobs, biotechnology jobs, Cell culture, biotechnology, stem cells culture, Investigational Medicinal Products, drug development, biomanufacturing and cGMP.

Posted in Jobs, NewsTagged in , , , , , , , ,